Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors

被引:0
作者
Alina Wong
An Le
Mei-Hsuan Lee
Yu-Ju Lin
Pauline Nguyen
Sam Trinh
Hansen Dang
Mindie H. Nguyen
机构
[1] University of Washington,Division of Gastroenterology
[2] Stanford University Medical Center,Department of Medicine
[3] Stanford University Medical Center,Division of Gastroenterology and Hepatology
[4] National Yang-Ming University,Institute of Clinical Medicine
来源
Scientific Reports | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The effect of metabolic syndrome on chronic liver diseases other than non-alcoholic fatty liver disease has not been fully elucidated. Our goal was to evaluate if metabolic syndrome increased the risk of liver-related complications, specifically hepatocellular carcinoma (HCC) and decompensation, in cirrhotic chronic hepatitis C (CHC) patients. We conducted a retrospective cohort study of 3503 consecutive cirrhotic CHC patients seen at Stanford University from 1997–2015. HCC developed in 238 patients (8-year incidence 21%) and hepatic decompensation in 448 patients (8-year incidence 61%). The incidence of HCC and decompensation increased with Hispanic ethnicity, diabetes, and number of metabolic risk factors. Multivariate Cox regression analysis demonstrated that, independent of HCV therapy and cure and other background risks, Hispanic ethnicity with ≥2 metabolic risk factors significantly increased the risk of HCC and hepatic decompensation. There was no interaction between Hispanic ethnicity and metabolic risk factors. All in all, metabolic risk factors significantly increase the risk of liver-related complications in cirrhotic CHC patients, especially HCC among Hispanics. As the prevalence of metabolic syndrome increases globally, targeted health interventions are needed to help curb the effects of metabolic syndrome in CHC patients.
引用
收藏
相关论文
共 40 条
[1]  
Aguilar M(2016)Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants Lancet 387 1377-1396
[2]  
Bhuket T(2015)Prevalence of the metabolic syndrome in the United States, 2003–2012 JAMA 313 1973-1974
[3]  
Torres S(2011)Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006 Diabetes Care 34 216-219
[4]  
Liu B(2016)Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 64 73-84
[5]  
Wong RJ(2017)Independent of Cirrhosis, Hepatocellular Carcinoma risk is increased with Diabetes and Metabolic Syndrome: A retrospective cohort study Am J Med 2 161-176
[6]  
Mozumdar A(2017)Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Lancet Gastroenterol Hepatol 12 293-299
[7]  
Liguori G(2016)Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection Gastroenterol Hepatol (N Y) 48 2137-2145
[8]  
Younossi ZM(2012)Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies Eur J Cancer 6 459-464
[9]  
Kasmari A(2008)Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients Clin Gastroenterol Hepatol 57 964-973
[10]  
Collaborators POH(2013)Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C Hepatology 47 1856-1862